Advertisement
Table 1 Baseline characteristics of the study population (n = 137)
| Characteristics | |
|---|---|
| Age (years) | 63.1 ± 7.9 |
| Sex (male/female) | 115/ 22 |
| Ethnicity (Caucasian/non-Caucasian) | 114/ 23 |
| BMI (kg/m2) | 29.2 ± 5.0 |
| Waist circumference (cm) | 106 ± 13 |
| Systolic blood pressure (mmHg) | 139 ± 17 |
| Diastolic blood pressure (mmHg) | 79 ± 9 |
| Metabolic syndrome¤ | 105 (77%) |
| Albuminuria (incl. micro-) | 34 (25%) |
| Current smoker | 23 (17%) |
| Previous myocardial infarction | 62 (45%) |
| Hypertension | 100 (73%) |
| Years of diabetes* | 9 (5, 15) |
| Creatinine (μmol/L)* | 79 (68, 91) |
| LDL (mmol/L)* | 2.0 (1.6, 2.6) |
| HDL (mmol/L)* | 1.12 (0.94, 1.38) |
| Triglycerides (mmol/L)* | 1.42 (1.06, 1.91) |
| HbA1c (%)* | 7.4 (6.8, 8.3) |
| Glucose (mmol/L)* | 8.1 (6.9, 9.8) |
| Insulin (pmol/L)* | 57 (33, 102) |
| C-peptide (pmol/L)* | 965 (713, 1290) |
| HOMA2-IR* | 1.3 (0.7, 2.1) |
| Anti-platelet therapy | 129 (94%) |
| Statin | 128 (93%) |
| Beta-blocker | 106 (77%) |
| ACE-inhibitor/ARB | 96 (70%) |
| Metformin | 101 (74%) |
| Sulfonylurea | 47 (34%) |
| Gliptin | 17 (12%) |
| Insulin/insulin-analogue | 26 (19%) |
